(Q40459857)

English

Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study.

scientific article published on January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

0 references

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Dunia de Miguel

4

object named as

Dunia De Miguel

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Carmen Burgaleta

6

object named as

Carmen Burgaleta

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Julio García-Suárez

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Helena Bañas

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Ignacio Arribas

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Teresa Pascual

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

1 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

136

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

276-285

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Venous thromboembolism in patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06438.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2006.06438.X

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40459857&oldid=1746360466"